- Home
- VIR vs KARO Comparison
VIR vs KARO Comparison
Compare VIR & KARO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- KARO
- Stock Information
- Founded
- VIR 2016
- KARO 2001
- Country
- VIR United States
- KARO Singapore
- Employees
- VIR N/A
- KARO N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- KARO Computer Software: Prepackaged Software
- Sector
- VIR Health Care
- KARO Technology
- Exchange
- VIR Nasdaq
- KARO Nasdaq
- Market Cap
- VIR 844.9M
- KARO N/A
- IPO Year
- VIR 2019
- KARO 2021
- Fundamental
- Price
- VIR $5.41
- KARO $44.40
- Analyst Decision
- VIR Strong Buy
- KARO Buy
- Analyst Count
- VIR 7
- KARO 2
- Target Price
- VIR $33.57
- KARO $44.00
- AVG Volume (30 Days)
- VIR 1.0M
- KARO 13.0K
- Earning Date
- VIR 05-07-2025
- KARO 05-14-2025
- Dividend Yield
- VIR N/A
- KARO 2.42%
- EPS Growth
- VIR N/A
- KARO 31.10
- EPS
- VIR N/A
- KARO 1.58
- Revenue
- VIR $20,861,000.00
- KARO $245,969,394.00
- Revenue This Year
- VIR N/A
- KARO $9.88
- Revenue Next Year
- VIR $10.65
- KARO $12.92
- P/E Ratio
- VIR N/A
- KARO $28.22
- Revenue Growth
- VIR N/A
- KARO 9.99
- 52 Week Low
- VIR $4.95
- KARO $25.80
- 52 Week High
- VIR $14.45
- KARO $50.54
- Technical
- Relative Strength Index (RSI)
- VIR 35.98
- KARO 59.24
- Support Level
- VIR $5.83
- KARO $42.86
- Resistance Level
- VIR $6.29
- KARO $44.92
- Average True Range (ATR)
- VIR 0.31
- KARO 1.64
- MACD
- VIR 0.02
- KARO 0.41
- Stochastic Oscillator
- VIR 28.80
- KARO 84.43
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.